- Home
- CMPS vs PRCT Comparison
CMPS vs PRCT Comparison
Compare CMPS & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPS | PRCT |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CMPS | PRCT |
|---|---|---|
| Price | $12.11 | $25.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $25.38 | ★ $35.44 |
| AVG Volume (30 Days) | ★ 4.0M | 1.2M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | N/A | $24.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $2.25 | $19.35 |
| 52 Week High | $14.76 | $62.17 |
Technical Indicators
Market Signals| Indicator | CMPS | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 44.04 |
| Support Level | $5.48 | $24.85 |
| Resistance Level | $14.76 | $26.41 |
| Average True Range (ATR) | 0.99 | 1.61 |
| MACD | -0.25 | -0.13 |
| Stochastic Oscillator | 35.33 | 7.69 |
Price Performance
Historical ComparisonAbout CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.